Accolate Claims "Cherry-Pick" Quality Of Life Data, FDA Letter Asserts
Executive Summary
Unsubstantiated claims and "cherry-picking" of quality-of-life data in promotions of Zeneca's asthma treatment Accolate (zafirlukast) are cited in a May 20 letter from FDA's Division of Drug Marketing, Advertising and Communications.